Idiopathic orbital inflammatory disease (IOID) is an idiopathic inflammatory process within the orbit that can result in permanent visual impairment. Although high-dose oral corticosteroids are currently the mainstay of therapy, their long-term usage can cause significant toxicity. We present a case of IOID that was successfully treated with the anti-CD20 monoclonal antibody rituximab following failed steroid sparing with conventional second-line immunosuppressive agents.
CITATION STYLE
Shao, E. H., Karydis, A., Gemenetzi, M., & Taylor, S. R. J. (2013). Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease. Case Reports in Ophthalmology, 4(3), 216–218. https://doi.org/10.1159/000356523
Mendeley helps you to discover research relevant for your work.